Tag: FDA biosimilars
Simon loxton
Lot-to-Lot Variability in Biologics and Biosimilars: What It Means for Patients and Providers
Lot-to-lot variability is a natural part of biologic and biosimilar manufacturing. Unlike generics, these drugs contain millions of slightly different protein versions in each batch. Learn how this variation is managed, why it doesn't affect safety, and what it means for patients and labs.
View More
12
